Olaparib suppresses oxLDL-enhanced NF-κB target-gene VCAM-1 protein expression in THP-1 monocytes.

Abstract

The cells were exposed to oxLDL, the PARP inhibitor olaparib (Olapa), or the NLRP3 inhibitor MCC950 (MCC), as indicated. The cell lysates were subjected to SDS-PAGE and immunoblotted with anti-VCAM-1 (upper panel) or anti-vinculin antibody (lower panel). The band densities, relative to vinculin (loading control), were quantified using ImageJ (NIH, Bethesda, MD). N = 4/group, * P<0.05 vs vehicle, #P<0.05 vs oxLDL only, one-way ANOVA, Newman-Keuls test. VCAM-1, vascular cell adhesion molecule 1.</p